BCL2 and breast cancer: Experimental evidence indicates that BCL-2 inhibition with Venetoclax and Hedgehog (Hh) pathway suppression in breast cancer can induce Treg conversion toward a Th17-like phenotype, reducing their immunosuppressive capacity, promoting effector cell infiltration, and amplifying antitumor responses.